Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study
Delveinsight
DECEMBER 3, 2020
It has been speculated that modifications to the epigenome drive cell ageing, especially a process known as DNA methylation, by which methyl groups are tagged onto DNA. Merck first collaborated with the biotech in a pact worth nearly USD 700 million two years ago, with an aim on a series of solid tumour targets.
52 
Let's personalize your content